Vicore Pharma publish annual report for 2017
2017 in brief
• Focused strategy in fibrotic diseases in the orphan drug field
• Strong safety data for C21 in Phase I applications
• Strengthened organization introducing new expertise
• Further development of C21 for additional fibrous diseases
• New collaboration with CRO for continued clinical program
Changes in results from previously published year-end report
• Reclassification of the holding in I-Tech to an associated company was reported in the year-end report as a capital loss. In the annual report this has been changed to being treated as a goodwill with a depreciation period of 5 years.
• Additional write-downs of patents of 3 789 KSEK from previously published financial statements.
| KSEK | 2017 | 2016 | 2015 | 2014 |
| Operating profit/loss | -12 793 | -6 649 | -4 543 | -5 340 |
| Profit/Loss after financial items | -12 855 | -6 652 | -4 570 | 13 687 |
| Earnings per share, SEK | -1,40 | -0,54 | -0,37 | 0,20 |
| Total equity as of 31 December | 112 968 | 75 597 | 81 930 | 53 696 |
| Cash flow from operating activities | -7 704 | -7 251 | -3 682 | -2 825 |
| Cash flow from investing activities | -22 779 | -13 977 | -5 657 | -2 390 |
| Cash and cash equivalents at year end | 24 019 | 4 266 | 25 175 | 1 710 |
For more information, please contact:
Per Jansson, CEO
M:+46 (0)70 917 47 46
per.jansson@vicorepharma.com
Hans Jeppsson, CFO
M: +46 (0)70 553 14 65
hans.jeppsson@vicorepharma.com
This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 09.00 CET on April 12, 2018